Global Lanolin (Wool Grease and Wool Fat) Market Report, Size, Share and Forecast 2026-2033

Why lanolin is priced by grade, not by the wool clip

Wool supply is at a record low, and lanolin is a by-product of it. Both parts of that are true and neither is controversial. What is worth a report is what the market has, and has not yet, done about it - because the conclusion most readers will draw from the trade figures, that a shrinking clip has failed to lift this market, is a conclusion the series cannot support.

Australia is among the largest wool producers and exporters in the world, and it sells a large share of its clip greasy. Its clip was 280.1 million kilograms in 2024/25, 11.8 per cent below the season before. The following season came in at an estimated 253.9 million kilograms, another 9.4 per cent down. The Australian Wool Production Forecasting Committee's second forecast for 2026/27 is 249.3 million kilograms, a further 1.8 per cent lower, on 56.3 million sheep shorn - a figure the committee itself describes as remaining "at historically low levels". Three consecutive seasons of decline, and across two of them the clip went from 317.6 million kilograms to 249.3, a fall of 21.5 per cent.

Lanolin comes out of that clip. A tonne of raw wool carries roughly 150 kilograms of wool grease, alongside 40 kilograms of suint, 150 kilograms of dirt and 20 kilograms of vegetable matter, leaving 640 kilograms of clean fibre. A shrinking clip is therefore a shrinking lanolin pool, and the arithmetic is unavoidable.

What does not follow is a shortage in the ordinary sense, and the figure usually produced to demonstrate that is the trade value. HS 150590 - wool grease and the fatty substances derived from it, including lanolin - traded USD 205 million worldwide in 2024. That was 13.5 per cent below 2023's USD 237 million. Across five years the series has grown at 1.04 per cent a year. The raw material became scarce and the trade became smaller - except that the second half of that sentence is doing work the data cannot carry.

The dates do not line up. The 2024 trade year was earned on a clip of 317.6 million kilograms. The seasons that carry the collapse in this report - 253.9 million kilograms in 2025/26 and a forecast 249.3 million in 2026/27 - sit ahead of that observation rather than behind it. A trade print taken before a supply shock cannot measure what the supply shock does to price, and this report should not have offered it as though it could.

One year down inside a five-year uptrend is a cycle, not a contraction. The same series has grown at 1.04 per cent a year across five years. A 13.5 per cent fall in a single year, in a commodity whose price ran up hard through 2021 and 2022, is what a cycle looks like coming off a peak. HS 150590 also mixes crude wool grease with refined material, so a shift in where refining happens, or more crude moving intra-firm, moves recorded value without moving a physical tonne across a border.

What survives the timing correction is narrower and more useful than the conclusion it replaces: prices in this market are set by grade rather than by the clip, and the grade split is structural rather than cyclical.

Lanolin's supply curve is nearly vertical in both directions, and the market does not clear on a single price. It clears by sorting. This report is about that sorting, because it is what actually determines what a buyer pays and what a supplier earns.

What is being counted

Lanolin is not one product, and the single largest source of error in published work on this market is treating it as one. There are at least four distinct materials with four different buyers:

• Crude wool grease - the raw centrifuged output of a scour, sold in drums and tankers into industrial uses.
• Technical grade refined lanolin - bleached, deodorised, sold into lubricants, corrosion protection, leather finishing and lower-grade cosmetics.
• Pharmacopoeia-grade Wool Fat - an article with a named monograph in the European Pharmacopoeia and USP/NF, manufactured to GMP, with a documented and audited supply chain.
• Lanolin derivatives - chemically modified materials made from wool grease by alkoxylation, fractionation, hydrolysis and acetylation, which are different molecules sold into different formulations.

This report measures the traded market for the first three at first sale, and treats derivatives as a downstream application rather than as volume, because a kilogram of ethoxylated lanolin alcohol is not a kilogram of lanolin and adding them produces a number that moves for reasons unrelated to the ingredient. The perimeter is stated here so that our figure can be compared with, and where necessary rejected in favour of, any other.

Two adjacent markets are worth following rather than folding in. The alkoxylated derivatives are nonionic surfactants in their own right, and their economics belong to the global surfactant market; the ethylene and propylene oxides they are built from are a separate feedstock business, covered in the global olefins market. A reader who adds this market to either of those is counting the same tonne twice.

The pool arithmetic, and why nobody agrees on it

The first step in any supply model is the grease content of the fleece, and it is here that the industry loses its footing. Two credible, authoritative conventions disagree by two thirds.

That is a spread of 1.67 times on the size of the raw-material pool for one of the world's largest wool-producing countries. It is not a rounding difference. It is the difference between a feedstock that is adequate and one that is structurally short, and it exists because the two figures measure different things: a mass balance on a scouring line, and a compositional estimate of the fleece. Neither is wrong. Neither is a supply number.

One detail in that table is worth naming, because it explains how the confusion spreads. The government manual's mass balance calls the 150 kilograms lanolin outright, while treating it as the grease removed at scouring; the industry calls the same material wool grease and reserves lanolin for the refined article. A scouring mass balance and a product specification are being read as though they were the same measurement, and part of the 1.67 times gap above is a vocabulary problem wearing a chemistry costume.

And the pool is not the supply. Between the fleece and the drum sit scouring, which separates grease from fibre and suint, and refining, which sorts the output into grades. Recovery depends entirely on how much of the clip is scoured in a plant that captures the grease. Australia sells a large share of its wool greasy, which means the grease is recovered wherever that wool is scoured - principally in China - and not where it was grown. The lanolin supply chain does not follow the paddock. It follows the scouring.

Physical sanity check: at an average cut of 4.29 kilograms greasy per head and 15 per cent grease content, one shorn sheep yields about 0.643 kilograms of lanolin. The world's lanolin supply is not decided by the cosmetics market. It is decided by how many sheep were shorn, and by how many of the plants that scour them are running a centrifuge.

Why the 2024 print fell, and what it cannot tell you

Three candidate explanations for that single year, ranked by how much of it each one can carry. They are not equally strong, and this report treats them that way rather than presenting all three as established.

First, wool grease is a waste stream, not a product. A scourer processes wool because the fibre is worth money. The grease has to be removed for the fibre to be saleable, and once separated it has to be moved. What the grease sells for is a credit against the cost of scouring, not a return that justifies running the plant. So output does not fall when the grease price falls: the plant runs for the fibre and the grease clears at whatever the market will pay. A supply curve like that is vertical on the way down as well as on the way up.

Second, and this one is inference rather than measurement, the grade mix may have moved down. When the pool tightens, the volume that is available is not evenly distributed across grades. The crude and technical material is what a scourer produces by default; pharmacopoeia-grade material requires a segregated, audited chain and a refiner willing to run it. A tighter pool therefore arrives on the market disproportionately as the cheapest grade, which pulls the average realised price down even as the headline raw material gets tighter.

Third, trade values are dominated by where the volume is, not where the value is. Refining has moved towards Asia. In 2024 the largest exporters of HS 150590 were China at USD 54.5 million, the United Kingdom at USD 35.9 million and Japan at USD 21.6 million. China's net trade surplus in the category was USD 52.6 million. The largest importers were Germany at USD 34.0 million, the United States at USD 26.7 million and the United Kingdom at USD 14.7 million. China and the UK both ran large surpluses; the US ran a deficit of USD 22.8 million and Germany USD 18.3 million.

That is a map of the refining business, and it says something uncomfortable: the country that scours and refines the most is not the country that holds the documentation moat. Both matter, and they are in different places.

The barbell is the market

Because there is no exchange, no futures contract and no published assessment for lanolin, the grade spread is not visible in any single quotation. It has to be assembled.

Take the measured trade value of USD 205 million and the plausible range for saleable recovered volume - 40,000 to 45,000 tonnes, consistent with the Australian pool alone at a capture rate well below theoretical - and the implied average traded unit value is USD 4,106 to 5,125 per tonne. That is the blended middle of the barrel.

Against it, a listed commercial offer for cosmetic-grade anhydrous lanolin meeting USP 38, quoted ex-Moscow in March 2025, stood at USD 14,700 per tonne including VAT. That is a single listed offer, not a benchmark, and it is a retail-adjacent quotation rather than a contract price. It is nonetheless enough to establish the shape: the same molecule, on the same day, at roughly 2.87 to 3.58 times the blended average, and 3.23 times the midpoint.

So the market is not a price. It is a spread of about three to one between the material a formulator can substitute and the material a monograph will not let a pharmaceutical manufacturer substitute. Every commercial decision in this ingredient is a decision about which end of that spread you are buying, and almost every published market size is an average across it - which is why they are all simultaneously defensible and useless.

How a shrinking pool actually clears

In a market with elastic demand and inelastic supply, a supply shock clears by price. In a market where one segment is inelastic and the other is not, it clears by sorting - and the sort is permanent, because the buyer who leaves does not come back when the clip recovers.

On the elastic side, the cosmetic formulator has a genuine exit and two reasons to take it. Lanolin is animal-derived, so any brand positioning as vegan or lanolin-free excludes it by definition. The wool-wax alcohols in it are also the recognised contact allergens, which gives a formulator a second, independent reason to reformulate. The alternative emollients and occlusives are numerous, and switching is a reformulation exercise rather than a regulatory one.

On the inelastic side, the pharmaceutical buyer has no exit. Lanolin is the most frequently used base substance for medicinal ointments. An otic, ophthalmic or topical preparation whose specification names Wool Fat cannot be reformulated without a variation, and the property that earns it the place - occlusivity, water-free, compatible with compromised skin - is not reproduced exactly by the alternatives. That buyer pays.

The consequence is that a smaller pool does not raise all boats. It rations the top grade and dumps the bottom grade, and the two prices move in opposite directions. That is the mechanism this report expects to see in the next two annual prints. It is not a description of the one just past, which was taken before the pool tightened. Anyone modelling this market with one elasticity has modelled it wrong.

Forecast

Base year 2025: USD 208.5 million. The forecast window runs 2026 to 2033 - seven intervals at 1.7 per cent compound - giving USD 234.6 million at 2033.

Where that opening number comes from, because it decides whether the rest of the page is honest: the last complete measured value in the series is 2024's USD 205.0 million, and 2025 is that figure carried forward one year at this report's own rate, 205.0 to 208.5. The opening year is therefore modelled rather than observed, and both observed numbers it stands on - 2024's 205.0 and 2023's 237.0 - are stated in the sections above, so the derivation can be checked, or replaced with a measured print when one exists.

The logic of that rate: volume is a structural decline of roughly 1.5 to 2 per cent a year on the clip, partly offset by more of the world's wool being scoured in plants that capture grease; price and mix add roughly 3.2 points as the pharmacopoeia-grade share of value rises. Net, 1.7 per cent.

The band matters more than the point. At 0.7 per cent - the case where the cosmetic exit accelerates and the mix shift fails to offset the clip - 2033 is USD 218.9 million. At 3.0 per cent - the case where documentation becomes a priced barrier and the top grade carries the market - it is USD 256.4 million. A buyer should plan against the low case and contract against the high one.

One falsifier is public, and it is the cleanest test this report offers. If the 2025 annual trade print for HS 150590 comes in materially above USD 208.5 million, the scarcity reached price faster than this base case assumes and 1.7 per cent is too low. If it comes in at or below USD 205 million with the clip already down a fifth, the sorting mechanism is doing more of the work than price is, and the low case is where a buyer should plan.

What would move this beyond its band

Not a wool forecast. The clip is already at a record low, and the trade figures have not yet been asked the question - so the uncertainty here is about timing and passage, not about whether a shortage exists. The events that would break the model are structural:

• A capture-technology shift. If grease recovery at scouring improves materially, volume decouples from the clip and the supply curve stops being vertical. Nothing currently suggests it is happening.
• A pharmacopoeia change. A monograph revision that admitted a synthetic or bio-identical substitute for Wool Fat would remove the inelastic buyer at a stroke and collapse the barbell. No such revision is in train.
• A traceability requirement applied to the raw material. Wool provenance schemes have moved from voluntary to contractual in apparel. If an equivalent audit requirement reached the grease, it would formalise the split between documented and undocumented material and make the grade spread an explicit premium rather than a negotiated one.
• Energy cost at the scour. Scouring is hot aqueous chemistry. The energy shock of 2026 raised the cost of running a plant whose by-product is already priced at the bottom of the barrel, which is an argument for fewer, larger, more efficient scours - and fewer capture points.

The number to watch is not the clip. It is the ratio between the top grade and the bottom, because that ratio is the only place in this market where a shortage can actually express itself - and it is the first number that will move when the 2025 trade print lands.

Table des matières

• Market overview and sizing
• Competitive landscape
• Value chain and the constrained node
• Investment activity
• Technology and innovation
• Market risk
• Regulatory landscape

Paysage concurrentiel

Concentrated at the top, commodity at the bottom

Lanolin refining is an old business with a thin elite. The structure that matters is not a share table – it is that the top of the market is defended by documents and the bottom of the market is defended by nothing at all.

Croda is the reference case and the closest thing this market has to an incumbent. Its founders, the chemist Mr Dawe and the entrepreneur Mr Crowe, began processing wool grease at Rawcliffe Bridge in the north of England in 1925. A century later the company refines lanolin at several manufacturing sites across three continents, which it presents explicitly as a supply-chain-risk argument, and produces high-purity material through a proprietary Super Refining process. Its Medilan range is made to GMP, complies with the European Pharmacopoeia and USP/NF monographs, is FDA inactive-ingredient-listed, is used at 1 to 10 per cent in topical formulations, and appears in otic, ophthalmic and vaginal preparations. The company also states that it sources wool grease in Australia and New Zealand because the origin satisfies the TSE risk assessment the pharmaceutical industry requires.

That last sentence is the whole competitive analysis. The moat is not the molecule, which is available to anyone with a centrifuge. It is a segregated, audited, transmissible provenance record attached to a pharmacopoeia article – and it took a hundred years and several regulatory regimes to build.

The second tier is Japanese and American. Nippon Fine Chemical is the long-established Japanese refiner whose export presence shows up in the trade data as the third-largest exporter of HS 150590 at USD 21.6 million in 2024. Its own disclosure is thinner than Croda’s and points the same way: it describes lanolin as purified from the lipid components that adhere to wool, sells it across pharmaceutical, cosmetic, industrial and feed applications, and states that it is working on transparency in its wool grease supply chain. A refiner advertising provenance rather than capacity is telling you where it thinks the competition is. RITA Corporation, operating since 1954, is a US supplier of personal care ingredients with a catalogue of more than 400 materials and custom blending capability, competing in the cosmetic and technical grades rather than at the monograph end. Both are credible, neither carries Croda’s regulatory position.

The third tier is Chinese, and it is the largest by volume. China was the largest exporter of HS 150590 in 2024 at USD 54.5 million, with a net trade surplus of USD 52.6 million. That is the refining and scouring capacity that grew up downstream of the wool trade itself, and it is the source of the crude and technical material that sets the bottom of the price barrel.

The fourth name worth knowing is not a refiner at all. LANOTEC is an Australian brand that sells lanolin-based industrial products – rust prevention, timber protection, marine and automotive corrosion control – which is the clearest demonstration that the industrial end of this market has a consumer-facing brand layer sitting on top of a commodity raw material. It is also the reminder that lanolin’s oldest recorded use was rust protection on sword sheaths, not skin care.

The five credible multi-line suppliers

On a strict definition – a supplier that can deliver more than one grade, across more than one region, with documentation – the count is five: Croda, Nippon Fine Chemical, RITA Corporation, LANOTEC at the industrial end, and Chinese refining capacity taken collectively. That is a count of credible participants, explicitly not a share calculation, and it excludes the long tail of traders and single-grade blenders who make up most of the registered entities in the category.

Intensity, and where it is felt

Competitive intensity is high and moderate at the same time, in different places. In crude and technical grades it is high: undifferentiated material, price-led, substitutable across suppliers, and clearing at whatever the bottom of the barrel will bear. In pharmacopoeia grades it is moderate: few qualified suppliers, high switching cost for the buyer, and competition conducted through audit files, batch consistency and security of supply rather than through price. A single competitor can therefore be a fierce rival in one product line and effectively absent in another on the same day.

The strategic error to avoid is reading the Chinese export volume as a competitive threat to the top of the market. It is not. It is the mechanism by which a tightening pool is absorbed without a visible shortage at the top – and that absorption is a mechanism, not a measurement. The 2024 print was earned on a clip of 317.6 million kilograms, and the two lost seasons arrive after it.

Chaîne de valeur

Four nodes, one of which is binding

The chain runs from a paddock to a formulation, and only one link in it is genuinely constrained. It is not the sheep.

Node one: the clip

Lanolin begins as a secretion of the sheep’s sebaceous glands that protects the skin and fleece. A tonne of raw wool carries roughly 150 kilograms of it, with 40 kilograms of suint, 150 kilograms of dirt and 20 kilograms of vegetable matter, leaving 640 kilograms of fibre. At Australia’s 2025/26 average cut of 4.29 kilograms greasy per head, one shorn sheep yields about 0.643 kilograms of lanolin.

That is the physical ceiling, and it is falling. Australia’s clip went from 317.6 million kilograms in 2023/24 to 280.1 in 2024/25, an estimated 253.9 in 2025/26 and a forecast 249.3 in 2026/27. World wool production in clean terms is estimated to be down 7 per cent between 2023 and 2025, with the main southern-hemisphere exporters down 13 per cent. The mechanism is not a decision about lanolin; it is sheepmeat economics, drought and land use. The IWTO’s own framing is a Catch-22 – as sheep numbers fall, sheepmeat prices rise, which puts further pressure on wool sheep numbers.

The fibre side of that equation is measured elsewhere. The global textile market carries the demand that actually pays for the clip, which is why a wool decision gets made on a textile balance sheet and not on a lanolin one. The nearest natural-fibre analogue is the alpaca fibre market – a small, specialised animal-fibre pool selling into the same knitwear demand, exposed to a producer base that shrinks for reasons unconnected to the fibre.

Node two: the scour, which is the real constraint

Scouring is hot aqueous detergent chemistry run across a series of bowls, followed by centrifugation to recover the grease. It is energy-intensive, water-intensive and capital-intensive, and it exists for the fibre. The grease is a credit against the cost of the operation, not the reason for it.

This is the binding node, for a simple reason: the grease can only be captured where the wool is scoured, and Australia sells a large share of its clip greasy. The grease from Australian wool is therefore recovered in whatever country buys the greasy wool – principally China – and the lanolin supply chain follows the scouring, not the paddock. The number and location of operating scours is the actual supply variable, and it consolidates slowly in the wrong direction: fewer, larger, more efficient plants mean fewer capture points.

The engineering constraint is well documented and old. Centrifuge recovery of wool grease was studied systematically in the 1960s, and the finding that has not changed is that recovery efficiency collapses at both very low and very high grease concentrations in the product, with an optimum around 15 per cent. A scourer is therefore always trading recovery rate against throughput, and a plant running for fibre economics will not optimise for the by-product.

Node three: the refiner, where value is created

Refining sorts the crude into grades. Crude grease is bleached, deodorised, filtered and, at the top of the range, super-refined to reduce oxidative impurities and colour. The same tonne of grease can leave as a drum of industrial material or as a batch of pharmacopoeia-grade Wool Fat, and the difference in realised price is roughly a factor of three.

That is where the economics of this chain actually live. Not in the yield, which is a property of the fleece, and not in the volume, which is a property of the clip, but in the sorting.

Node four: the formulator, and the fork in demand

Downstream, the buyer is either substituting or not. Cosmetic and personal care formulators use lanolin as an emollient and occlusive in barrier creams, hand and face creams, nappy creams and lip products, and have a long list of alternatives. Pharmaceutical manufacturers use it because a monograph names it: it is the most frequently used base substance for medicinal ointments, and it appears in topical steroids, otic preparations and nipple creams for breastfeeding mothers. Lanolin oil is also used as a plasticiser and dispersant in medicines, and lanolin wax as a stabilising and binding agent.

Where a reformulation decision actually gets made is worth naming, because it is not made by the pharmaceutical buyer. It is made in high-volume consumer categories, where the occlusivity that earns lanolin its place can be bought from a vegetable emollient against a one-line specification change. The India baby care market is one of those pools: nappy and barrier products are exactly the formulations where the substitution is easiest, and where volume growth compensates for a thinner margin.

The fork is the point. The value chain does not terminate in one demand curve. It terminates in two, with opposite elasticities, and the sorting at node three is what reconciles them.

Activité d'investissement

Nobody is building capture capacity, and the arithmetic says why

Capital in this market does not flow to the obvious place. The obvious place is grease recovery at the scour, and it is starved for a structural reason: a by-product cannot justify the capital expenditure of the process that produces it.

Consider the economics from a scourer’s seat. The plant exists to clean fibre. Grease recovery requires centrifuges, tanks, heat and labour, and returns material that clears at USD 4,000 to 5,000 a tonne at the bottom of the barrel. Against a fibre business whose output is worth far more per tonne, the grease credit is a rounding item on the operating statement – important enough to capture, never important enough to expand. When the grease price falls, the plant keeps running, because the fibre still pays. That is a supply curve that does not respond to its own price, and no investment case can be built on it.

The same logic explains the consolidation. Fewer, larger and more efficient scours make sense on fibre economics, and they reduce the number of places where grease can be captured. Capital discipline in scouring is, functionally, a slow contraction of lanolin supply – without anyone in the lanolin market making a decision.

Where money actually goes

Three places, none of them capacity.

Documentation and compliance. The highest-returning investment in this industry is not a centrifuge, it is an audit file. GMP manufacture, pharmacopoeia monograph compliance, a TSE risk assessment, a segregated supply chain, batch-to-batch consistency and FDA inactive-ingredient listing are what convert a USD 4,000 tonne of grease into a USD 14,700 tonne of excipient. Every one of those is a fixed cost with a regulatory return, and none of them can be replicated quickly by a competitor with cheaper feedstock.

Derivative capacity. Alkoxylation, fractionation, hydrolysis and acetylation convert wool grease into materials with different functions and different buyers. Derivative capacity is where incremental capital can earn a return, because the output is a performance chemical rather than a commodity, and the feedstock advantage is already secured if you own the refinery.

Securing origin. Croda’s stated policy of sourcing wool grease in Australia and New Zealand for TSE compliance is an investment in provenance, and it is defensible precisely because the alternative origins cannot supply the same documentation. In a market where the raw material is shrinking, the asset worth owning is the right to buy the shrinking raw material on the terms a regulator accepts.

What investors should read from the trade data

The geography of the category’s surplus tells you where capital has already been deployed. China ran a net surplus of USD 52.6 million in HS 150590 in 2024 and the UK USD 21.2 million, while the United States ran a deficit of USD 22.8 million and Germany USD 18.3 million. The refining and scouring capacity sits in Asia; the regulated demand sits in Europe and North America. That gap is a logistics and documentation business, and it is stable, unglamorous and difficult to displace.

There is no greenfield story here. Anyone presenting one should be asked which fibre plant is going to fund the centrifuge, and what happens to their model when the answer is none.

Technologie et innovation

The innovation is in purification and paperwork, not in yield

Lanolin is one of the most analytically awkward materials in commercial chemistry, and that awkwardness is the whole basis of technical competition.

It is a complex mixture of esters, di-esters and hydroxy-esters of C12 to C35 lanolin alcohols and C7 to C41 lanolic acids. Estimates put the number of distinct esters at up to 20,000, some liquid and some solid, giving a semi-solid mixture with a melting point around 40 degrees Celsius. You cannot characterise that mixture completely, and you cannot synthesise a substitute that matches it ester for ester. What you can do is control it – and control is what buyers are paying for.

Super refining and the colour problem

The commercial frontier is purification. Croda’s Super Refining process is described as minimising oxidative impurities and reducing colour, with the stated benefits being batch-to-batch consistency, shelf life and active-ingredient stability; the Ultra grade is nearly white and positioned for the most sensitive dermatological applications. That is a technical achievement with a commercial function: an excipient that varies between batches is unusable in a regulated formulation regardless of how good its average properties are.

Notice what this is not. It is not a yield improvement. Nobody has found a way to get more grease out of a fleece, and the centrifuge physics that govern recovery – optimum product concentration around 15 per cent, efficiency collapsing at both extremes – have been understood since the 1960s. The technology race is downstream of the centrifuge, in the refinery, and it is a race about consistency rather than quantity.

The sensitiser problem, and the technical answer to it

The wool-wax alcohols in lanolin are the recognised contact allergens, and that is a genuine technical liability in cosmetic formulation. The industry’s answer has been to remove or reduce them, and to market the resulting ultra-purified grades – which is simultaneously a technical fix, a regulatory convenience and a marketing position. It also has a strategic consequence: the same purification capability that makes a grade suitable for sensitive skin makes it suitable for a pharmaceutical monograph, so the technical investment serves both ends of the demand fork at once.

Derivatives as the innovation surface

Because lanolin itself is hard to modify usefully and impossible to replicate, the innovator’s freedom sits in its derivatives. Alkoxylation, fractionation, hydrolysis and acetylation each produce materials with different solubility, feel and function, sold into different applications from emulsifiers to conditioning agents. This is where a refiner can create something a competitor cannot immediately match, and it is why derivative capability, not refining capacity, is the part of the chain worth owning.

The substitution technology, which is the real competitive threat

The most consequential innovation in this market is happening outside it. Bio-based emollients and occlusives – including vegetable-derived alternatives and synthetic barrier materials – have improved to the point where a cosmetic formulator can replace lanolin with no meaningful performance loss, and can simultaneously claim a vegan and allergen-free position. Every advance there narrows the elastic half of lanolin demand permanently.

Against that, the pharmaceutical half is protected by a monograph rather than by performance. No technology currently on the market changes the fact that a specified preparation must contain the specified article. That asymmetry – innovation freely available on one side of the demand fork and structurally blocked on the other – is the most important technological fact about this market, and it is not a fact about lanolin at all.

Risque de marché

Six risks, and one of them is unusual

The risks here do not look like the risks in a growth market. The distinctive one is that an improvement in the headline supply picture may be bad for value.

Ranked risks

1. Permanent cosmetic exit. Each reformulation away from lanolin removes a buyer who does not return when supply recovers. This is the slow, structural risk, and it is the reason the low case exists. It is driven by vegan positioning and by the sensitiser profile, neither of which reverses.
2. Grade-mix dilution. A tighter pool arrives disproportionately as crude and technical material, which pulls the average realised price down while the raw material gets scarcer. The 2024 fall of 13.5 per cent in trade value is often read as this mechanism at work, and it may be, but the reading has to survive the timing: that print was earned on a clip of 317.6 million kilograms, and the two lost seasons sit after it. The mechanism is still the most likely source of a downside surprise in any revenue forecast, which is why it ranks here on structure rather than on one data point.
3. Wool recovery, which is not good news. If the clip rebounds, the volume that returns is bottom-grade grease. It would depress the price of the material that is already cheap, and it would not relieve the constraint at the top, because that constraint is documentation rather than molecules. A wool recovery is a bearish event for blended value.
4. Capture concentration. Because a large share of the world’s greasy wool is scoured in China, the capture point for the pool is concentrated in one jurisdiction. Tariff, energy or logistical disruption there is a supply risk to the whole market, and it is not diversifiable by buying from a different refiner – several refiners buy the same crude.
5. Energy cost at the scour. Scouring is hot aqueous chemistry, and the energy shock of 2026 raised the operating cost of a plant whose by-product is priced at the bottom of the barrel. The rational response is fewer, larger plants, which reduces capture points and reinforces risk four.
6. Data risk. The two authoritative conventions on grease content differ by 1.67 times, which means the size of the raw-material pool is not known to within two thirds. Any supply model built on one convention is a model built on an assumption nobody has validated.

The one risk that would break the model

A pharmacopoeia revision admitting a synthetic or bio-identical substitute for Wool Fat. That single event would remove the inelastic buyer, collapse the grade barbell, and turn a sorted market back into a plain commodity. No such revision is in train, and the conservatism of the monograph system makes it unlikely – but it is the only event that would invalidate the structure this report describes rather than perturb it.

What the band is for

The forecast runs from USD 218.9 million in 2033 at 0.7 per cent to USD 256.4 million at 3.0 per cent, against a base case of USD 234.6 million at 1.7 per cent, on a 2025 base of USD 208.5 million. The spread is not hedging. It is the honest consequence of a market where volume is structurally declining, mix is structurally improving, and the two effects are of similar magnitude. A buyer should plan on the low case and contract on the high one.

Paysage réglementaire

Compliance is the product

In most commodity markets, regulation is a constraint on the business. Here it is the business. The difference between a commodity grease and a pharmaceutical excipient is almost entirely regulatory, and the regulation is what creates the price spread this report is about.

The pharmacopoeia layer

Wool Fat is a named article with a monograph in the European Pharmacopoeia and in USP/NF. A supplier claiming pharmaceutical grade must manufacture to GMP, meet the monograph, and be able to demonstrate it batch after batch. Inactive-ingredient listing with the US FDA is a further gate for use in registered drug products. The material is used at roughly 1 to 10 per cent in topical formulations and appears in otic, ophthalmic and vaginal preparations, which are the most exacting contexts in the whole category.

This is not a barrier that can be bought. A new entrant with cheaper feedstock still has to build the quality system, run the validation and accumulate the history, and while it does, the incumbent is being paid a multiple for the same molecule.

The TSE layer, and why origin is a regulatory question

Transmissible spongiform encephalopathy risk assessment is the reason the pharmaceutical lanolin chain is deliberately separated from the bulk scouring chain. Croda’s stated practice of sourcing wool grease in Australia and New Zealand because that origin satisfies the industry’s TSE risk assessment is the clearest available evidence that provenance is a regulatory precondition rather than a marketing preference. It also means that a supplier’s geography is part of its licence to sell, and that material from an unapproved origin cannot be substituted into a pharmaceutical formulation at any price.

The cosmetic layer, which pushes the other way

Cosmetic regulation creates the opposite pressure. Lanolin is animal-derived, which is decisive for any brand making a vegan claim, and the wool-wax alcohols are the recognised contact allergens, which brings the ingredient within allergen-declaration discipline. Add the veterinary and animal-by-product documentation that accompanies an animal-derived raw material – a listed Russian offer for USP 38 material, for instance, is supplied with veterinary certificates alongside the quality and safety certificates – and the administrative burden per kilogram is high for a formulator who has a workable alternative.

So the same rulebook that makes lanolin indispensable at the top of the market makes it inconvenient at the bottom. Regulation is not a single force here; it is two forces pulling the grade structure apart.

Classification and trade

The category sits in HS 1505, with crude wool grease and the derived materials including lanolin separated at the six-digit level. The distinction matters commercially because crude material and refined material are different products with different duty treatment and different documentation, and it matters analytically because published statistics for HS 150590 include derivatives, which inflates any tonnage-based reading of lanolin. Total trade is small – USD 205 million worldwide in 2024, under 0.005 per cent of world trade, and ranked 3,728th of 4,762 products by value – so tariffs rarely determine outcomes, but classification determines what is being counted.

The traceability question, not yet asked

Wool provenance schemes have moved from voluntary to contractual in apparel, and the IWTO’s reporting shows certification premiums recovering from a collapse in 2023 and 2024. Those schemes govern the fibre. They do not yet govern the grease. If an equivalent audit requirement ever reached the scouring stage, it would formalise the split between documented and undocumented material and convert the negotiated grade spread into an explicit, published premium – which would be the single largest structural change in this market’s pricing in a century.